San Francisco has spent billions on its homelessness and addiction crises over the past decade, cycling through harm reduction strategies, safe injection sites, and a bureaucratic maze of social services that have — let's be generous — produced mixed results. Now, a genuinely promising lead is emerging from an unexpected corner: the same class of drugs that's helping your coworker fit into skinnier jeans.

GLP-1 receptor agonists — the drug class behind Ozempic and Wegovy — are being explored by SF addiction researchers as a potential treatment for substance use disorders. And early signals are encouraging enough that scientists are calling these drugs "almost certainly going to be a major tool in the toolbox" for treating addiction.

Here's the short version of the science: GLP-1 drugs appear to dampen the brain's reward pathways — the same circuits hijacked by alcohol, opioids, nicotine, and other substances. If you've heard anecdotal reports of Ozempic users suddenly losing interest in their nightly wine habit, this is why. Researchers are now working to move beyond anecdotes and into rigorous clinical data.

Let's be clear-eyed about where we are. The research is early-stage, and anyone promising a silver bullet for addiction is selling you something. But here's what makes this development worth watching from a fiscal perspective: pharmaceutical interventions that actually reduce substance dependency could dramatically lower the cost of the city's sprawling addiction services infrastructure. San Francisco currently spends north of $1 billion annually on homelessness-related programs, a significant chunk of which is tied to substance use disorders.

If a GLP-1 prescription can do what tens of millions in "innovative programming" hasn't — actually move the needle on addiction recovery rates — then this could represent the kind of cost-effective, results-driven approach that the city desperately needs.

Nobody's saying we should replace treatment programs with a shot. But maybe, just maybe, we should be allocating serious research dollars toward something that has biological plausibility and measurable outcomes — instead of doubling down on strategies that keep the bureaucracy fed while the crisis persists.